Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT

Bone Marrow Transplantation volume 45, pages 1404–1407 (2010)Cite this article

Subjects

Abstract

Monitoring of minimal residual disease (MRD) after allogeneic (allo)-SCT for myelofibrosis (MF) allows recognizing the depth of remission and thus guides application of appropriate therapeutic interventions. MPL W515L/K mutations, which are detected in 5–10% of JAK2V617F-negative patients, may be useful for this purpose. Using a highly sensitive quantitative PCR method, we tested 90 patients with MF who underwent allo-SCT for the presence of MPL W515L/K mutations. Two patients with primary MF were found to harbor MPLW515L while no patient was positive for MPLW515K mutation. Both patients were JAK2V617F negative and cleared the mutation rapidly after allo-SCT and remained negative for a median follow-up of 19 months. The results of molecular monitoring correlated well with other remission parameters such as normalization of peripheral blood counts and morphology and complete donor chimerism. We conclude that MPLW515L can be cleared after allo-SCT and hence may be used as an MRD marker in a proportion of JAK2V617F-negative MF patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Tefferi A . Survivorship and prognosis in myelofibrosis with myeloid metaplasia. Leuk Lymphoma 2006; 47: 379–380.

    Article  PubMed  Google Scholar 

  2. Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005; 20: 879–889.

    CAS  PubMed  Google Scholar 

  3. Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690–697.

    Article  PubMed  Google Scholar 

  4. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E . Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000; 26: 697–699.

    Article  CAS  PubMed  Google Scholar 

  5. Kroger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113: 1866–1868.

    Article  PubMed  Google Scholar 

  6. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ghaderi M, Stromberg O, Porwit A . Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders. Int J Lab Hematol 2008 (e-pub ahead of print).

  8. Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn 2008; 10: 435–441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316–1321.

    Article  PubMed  Google Scholar 

  10. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008; 22: 1557–1566.

    Article  CAS  PubMed  Google Scholar 

  11. Fehse B, Chukhlovin A, Kuhlcke K, Marinetz O, Vorwig O, Renges H et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 419–425.

    Article  CAS  PubMed  Google Scholar 

  12. Percy MJ, McMullin MF . The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol 2005; 23: 91–93.

    Article  CAS  PubMed  Google Scholar 

  13. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–3476.

    Article  CAS  PubMed  Google Scholar 

  14. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137: 244–247.

    Article  CAS  PubMed  Google Scholar 

  15. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141–149.

    Article  CAS  PubMed  Google Scholar 

  16. Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009; 94: 141–144.

    Article  PubMed  Google Scholar 

  17. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135: 683–687.

    Article  CAS  PubMed  Google Scholar 

  18. Hussein K, Bock O, Theophile K, Schlue J, Ballmaier M, Kroger N et al. Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. Blood 2009; 113: 1391–1392.

    Article  CAS  PubMed  Google Scholar 

  19. Chaligne R, James C, Tonetti C, Besancenot R, Le Couedic JP, Fava F et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007; 110: 3735–3743.

    Article  CAS  PubMed  Google Scholar 

  20. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370–3373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009; 23: 852–855.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Ronan Chaligne and Jean-Pierre Le Couedic for providing the sequences of primers and probes for designing MPL-PCR assay. We also thank Alessandro M Vannucchi for providing the plasmids for mutated and wild-type MPL. HA is a recipient of an EBMT-AMGEN fellowship 2008.

Author information

Author notes

  1. H Alchalby and A Badbaran: These authors contributed equally to this work.

Authors and Affiliations

  1. Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    H Alchalby, A Badbaran, B Fehse, U Bacher, A R Zander & N Kröger

  2. Hannover Medical School, Institute of Pathology, Hannover, Germany

    O Bock

Authors
  1. H Alchalby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Badbaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Fehse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U Bacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A R Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Kröger.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alchalby, H., Badbaran, A., Bock, O. et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 45, 1404–1407 (2010). https://doi.org/10.1038/bmt.2009.367

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.367

Keywords

This article is cited by

Search

Advanced search

Quick links